<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746693</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-291012</org_study_id>
    <nct_id>NCT01746693</nct_id>
  </id_info>
  <brief_title>Neurovascular Coupling in Subjects With Amblyopia</brief_title>
  <official_title>Neurovascular Coupling in Subjects With Amblyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amblyopia is a developmental condition that is characterized by reduced vision of the eye due
      to the presence of a sensory impediment during visual development, such as strabismus (ocular
      misalignment) or anisometropia (unequal refractive error), occurring early in life. Recent
      studies in humans and animals point towards a cortical locus for the processing deficit in
      amblyopia, revealing sensory deficits at the signal cell level. If changes in retinal
      neuronal function are also present, is unknown.

      Like in the brain, blood flow in the retina is coupled to neuronal activity. This phenomenon
      has been measured by different study groups with non invasive techniques in the brain and
      retina. It has been shown in previous studies that stimulating the retina with diffuse
      luminant flickering light increases retinal vessel diameter and blood flow. However, it is
      unknown whether this is also the case in the retina of amblyopic eyes. Additionally, the
      introduction of blood oxygen level dependent (BOLD) fMRI also makes it possible to directly
      access the vascular response in the brain to visual stimuli.

      Therefore, the aim of the present study is to investigate the effect of luminant flickering
      light on retinal vessel diameter and retinal blood flow in subjects with amblyopia. Also,
      oxygen saturation in retinal vessels will be assessed as well as pattern ERG for assessment
      of retinal function. Additionally, a high resolution image of the visual pathway will be
      taken with 7 Tesla MRI to investigate whether anatomical or functional alterations are
      present.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Vessel Diameter in Response to Flickering Light (DVA)</measure>
    <time_frame>once on the study day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal (arterial and venous) oxygen saturation</measure>
    <time_frame>once on the study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal blood velocity in response to flickering light</measure>
    <time_frame>once on the study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High resolution functional and anatomical imaging of the visual pathway</measure>
    <time_frame>once on the study day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inner Retinal Function</measure>
    <time_frame>once on the study day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amblyopia ex Strabismus</condition>
  <condition>Amblyopia ex Anisometropia</condition>
  <arm_group>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 male and female volunteers with amblyopia ex anisometropia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 male and female volunteers with amblyopia ex strabismus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy male and female control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Vessel Analyzer</intervention_name>
    <description>retinal vessel diameter, retinal oxygen saturation</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laser Doppler Velocimetry</intervention_name>
    <description>retinal blood flow velocity, retinal blood flow</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>7-Tesla MRI</intervention_name>
    <description>High resolution functional and anatomical imaging of the visual pathway</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pattern electroretinography</intervention_name>
    <description>inner retinal function</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fourier domain optical coherence tomography</intervention_name>
    <description>Blood flow in retina.</description>
    <arm_group_label>amblyopia ex anisometropia</arm_group_label>
    <arm_group_label>amblyopia ex strabismus</arm_group_label>
    <arm_group_label>control subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 18 and 55 years

          -  Non-smokers (for at least 6 months)

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

          -  Normal ophthalmic findings except amblyopia on one eye resulting from anisometropia or
             strabismus with a visual acuity of Snellen ≤ 0.3 with best correction on the amblyopic
             eye and Snellen 0.9 or better in the contralateral eye (for subjects with amblyopia)

          -  Normal ophthalmic findings with visual acuity of Snellen ≥ 1.0 in both eyes (for
             control subjects)

        Exclusion Criteria:

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  Presence or history of a severe medical condition as judged by the clinical
             investigator

          -  Regular use of medication, abuse of alcoholic beverages, participation in a clinical
             trial in the 3 weeks preceding the study (except oral contraceptives)

          -  Blood donation during the previous three weeks

          -  Pregnancy, planned pregnancy or lactating

          -  Any metallic, electric, electronic or magnetic device or object not removable except
             dental fillings

          -  Claustrophobia

          -  Epilepsia, history or family history of seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerhard Garhoefer, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>2981</phone_ext>
    <email>gerhard.garhoefer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhoefer, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>2981</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Gerhard Garhoefer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr.</investigator_title>
  </responsible_party>
  <keyword>retinal vessel diameter</keyword>
  <keyword>retinal oxygen saturation</keyword>
  <keyword>high resolution functional and anatomical imaging</keyword>
  <keyword>inner retinal function</keyword>
  <keyword>flicker response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Anisometropia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

